| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000020307 |
| Receipt No. | R000023448 |
| Official scientific title of the study | A study for evaluating the effects of oral intake of lactic acid bacteria on immune function. A randomized, double-blind, placebo- controlled trial. |
| Date of disclosure of the study information | 2015/12/24 |
| Last modified on | 2016/08/08 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | A study for evaluating the effects of oral intake of lactic acid bacteria on immune function. A randomized, double-blind, placebo- controlled trial. | |
| Title of the study (Brief title) | A study for evaluating the effects of oral intake of lactic acid bacteria on immune function. | |
| Region |
|
|
| Condition | ||
| Condition | None (Healthy adults) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy of oral intake of lactic acid bacteria on immune functions. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Evaluation of cytokines production and expression levels of anti-viral genes of peripheral blood mononuclear cells stimulated by viruses at 4 weeks after intervention. |
| Key secondary outcomes | Activities of dendritic cells in peripheral blood at 4 weeks after intervention. (Cell surface expression levels of dendritic cells makers.) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Lactic acid bacteria, 1 portion of food per day for 4 weeks. | |
| Interventions/Control_2 | Placebo (not containing lactic acid bacteria), 1 portion of food per day for 4 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Males and females aged from 20 to less than 65 years old, when giving the informed consent.
2)Individuals who have low activities of immune cells in peripheral blood. 3)Individuals who give the informed consents in writing, after receiving enough explanation of the purpose and details of the study, understanding the study well, and deciding to attend the study with their own will. |
|||
| Key exclusion criteria | 1)Individuals who can't stop drinking for 2 days until the screening and each checkup.
2)Individuals who can't stop eating foods containing lactic acid bacteria and oligosaccharide during this study. 3)Individuals who can't stop eating foods which may activate immune functions. 4)Individuals who have tendency to get diarrhea by eating dairy product. 5)Individuals who have a history of irritable bowel syndrome and Crohn's disease. 6)Individuals who was vaccinated and who may receive it this year. 7)Individuals who have a medical history of serious disease (e.g., diabetes, liver disease, kidney disease, and/or heart disease), thyroid gland disease, adrenal gland disease, and/or metabolic disorder. 8)Individuals who have chronic diseases and use medicines continuously. 9)Individuals who have under treatment or a history of drug addiction and/or alcoholism. 10)Individuals who are judged as unsuitable for the study based on the results of blood test. 11)Individuals with excessive alcohol-drinking behaviors. 12)Individuals who have a medical history of diseases affecting digestion and absorption. 13)Individuals who have a medical history of hay fever. 14)Individuals having food allergy. 15)Individuals who are pregnant, breastfeeding, or planning to be pregnant in the near future. 16)Individuals who are participating or willing to participate in other clinical trials or in the last 3 months. 17)Individuals who and whose family work for a company manufacturing or selling healthy foods or functional foods. 18)Individuals who are judged unsuitable for this study by the investigator for other reasons. |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Haruhi Sugimura |
| Organization | C'est la vie Shimbashi Clinic |
| Division name | Medical office |
| Address | 2-39-3 Nishishimbashi, Minato-ku, Tokyo |
| TEL | 03-5408-8671 |
| h-sugimura@shinkokai.jp | |
| Public contact | |
| Name of contact person | Eiji Yoshikawa |
| Organization | KSO Corporation |
| Division name | Sales department |
| Address | 1-9-7 Shibaura, Minato-ku, Tokyo, Japan |
| TEL | 03-3452-7733 |
| Homepage URL | |
| yoshikawa@kso.co.jp | |
| Sponsor | |
| Institute | KSO Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kirin Company, Limited |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団進興会 セラヴィ新橋クリニック/Medical Corporation Shinkou Kai C'est la vie Shinbashi Clinic |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023448 |